BCL6 Recombinant Monoclonal Antibody

Code: CSB-RA131953A0HU

Rate （N/A）
Review （0）

Size:

50μl100μl

US$210

Quantity:

Species Reactivity: Human

Application: ELISA, IHC, FC

Send an Inquiry

Start an on-line Chat

Online ordering is currently available for U.S. customers only. For orders outside the U.S., please kindly submit an inquiry or start a chat with us.

Product Details
Related Products
Customer Reviews and Q&A
Target Background

Product Details

Uniprot NO.

P41182

Target Names

BCL6

Alternative Names

B-cell lymphoma 6 protein (BCL-6) (B-cell lymphoma 5 protein) (BCL-5) (Protein LAZ-3) (Zinc finger and BTB domain-containing protein 27) (Zinc finger protein 51), BCL6, BCL5 LAZ3 ZBTB27 ZNF51

Species Reactivity

Human

Immunogen

A synthesized peptide derived from Human BCL6

Conjugate

Non-conjugated

Clonality

Monoclonal

Isotype

Rabbit IgG

Clone No.

6E3

Purification Method

Affinity-chromatography

Concentration

It differs from different batches. Please contact us to confirm it.

Buffer

Rabbit IgG in 10mM phosphate buffered saline , pH 7.4, 150mM sodium chloride, 0.05% BSA, 0.02% sodium azide and 50% glycerol.

Form

Liquid
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.

Scope Application

ELISA Protocol Immunohistochemistry (IHC) Protocol Flow Cytometry (FC) Protocol

Recommended Dilution

Application	Recommended Dilution
IHC	1:50-1:200
FC	1:50-1:200

Storage

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Lead Time

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Note: All of our proteins are default shipped with normal blue ice packs, if you request to ship with dry ice, please communicate with us in advance and extra fees will be charged.

Usage

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Datasheet & COA

Antibody FAQs

Images

IHC image of CSB-RA131953A0HU diluted at 1:33 and staining in paraffin-embedded human testis tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a Goat anti-rabbit polymer IgG labeled by HRP and visualized using 0.73% DAB.
Overlay Peak curve showing Jurkat cells stained with CSB-RA131953A0HU (red line) at 1:50. The cells were fixed in 4% formaldehyde and permeated by 0.2% TritonX-100. Then 10% normal goat serum to block non-specific protein-protein interactions followed by the antibody (1µg/1*10⁶cells) for 45min at 4℃. The secondary antibody used was FITC-conjugated Goat Anti-rabbit IgG(H+L) at 1:200 dilution for 35min at 4℃.Control antibody (green line) was rabbit IgG (1µg/1*10⁶cells) used under the same conditions. Acquisition of >10,000 events was performed.

Description

BCL6 serves as a master transcriptional repressor essential for germinal center formation and B-cell differentiation, making it a critical target in lymphoma research and immunology studies. This zinc finger and BTB domain-containing protein plays a pivotal role in regulating the germinal center reaction, and its dysregulation through chromosomal translocations or aberrant expression is strongly implicated in diffuse large B-cell lymphoma and follicular lymphoma pathogenesis.

This recombinant monoclonal antibody, clone 6E3, offers the reproducibility that demanding research requires. Generated against a synthetic peptide derived from human BCL6, the recombinant format ensures sequence-defined consistency between lots, eliminating the variability that can compromise longitudinal studies or multi-site collaborations. The rabbit IgG isotype and affinity-chromatography purification deliver the specificity needed for reliable target detection.

Validation across multiple platforms demonstrates genuine experimental flexibility. Immunohistochemistry testing in paraffin-embedded human testis tissue confirms robust performance in archival samples, with recommended dilutions of 1:50-1:200 providing optimization range for different tissue contexts. Flow cytometry validation using Jurkat cells, a T-cell leukemia line, shows clear positive signal separation from isotype control, confirming utility for intracellular detection of BCL6 in suspension cell populations. The antibody is also validated for ELISA applications.

For researchers investigating germinal center biology, B-cell malignancies, or the broader landscape of transcriptional regulation in cancer, this antibody provides a dependable tool for exploring BCL6 function across complementary experimental approaches. Its performance in both fixed tissue and permeabilized cell applications supports comprehensive characterization of BCL6 expression patterns in human samples.

Customer Reviews and Q&A

■ Customer Reviews

Submit a Review here

Target Background

Function(From Uniprot)

Transcriptional repressor mainly required for germinal center (GC) formation and antibody affinity maturation which has different mechanisms of action specific to the lineage and biological functions. Forms complexes with different corepressors and histone deacetylases to repress the transcriptional expression of different subsets of target genes. Represses its target genes by binding directly to the DNA sequence 5'-TTCCTAGAA-3' (BCL6-binding site) or indirectly by repressing the transcriptional activity of transcription factors. In GC B-cells, represses genes that function in differentiation, inflammation, apoptosis and cell cycle control, also autoregulates its transcriptional expression and up-regulates, indirectly, the expression of some genes important for GC reactions, such as AICDA, through the repression of microRNAs expression, like miR155. An important function is to allow GC B-cells to proliferate very rapidly in response to T-cell dependent antigens and tolerate the physiological DNA breaks required for immunglobulin class switch recombination and somatic hypermutation without inducing a p53/TP53-dependent apoptotic response. In follicular helper CD4(+) T-cells (T(FH) cells), promotes the expression of T(FH)-related genes but inhibits the differentiation of T(H)1, T(H)2 and T(H)17 cells. Also required for the establishment and maintenance of immunological memory for both T- and B-cells. Suppresses macrophage proliferation through competition with STAT5 for STAT-binding motifs binding on certain target genes, such as CCL2 and CCND2. In response to genotoxic stress, controls cell cycle arrest in GC B-cells in both p53/TP53-dependedent and -independent manners. Besides, also controls neurogenesis through the alteration of the composition of NOTCH-dependent transcriptional complexes at selective NOTCH targets, such as HES5, including the recruitment of the deacetylase SIRT1 and resulting in an epigenetic silencing leading to neuronal differentiation.

Gene References into Functions

our exploratory study suggests that EOMES, BCL6 and GZMB gene expression are aberrant within the PB T cell transcriptome of HT patients. The association of this transcription signature with the heterogeneity of HT and disease control is suggested. PMID:29319368
Cryptic t(3;8)(q27;q24) and/or MYC-BCL6 linkage associated with MYC expression by immunohistochemistry is frequent in multiple-hit B-cell lymphomas PMID:28665415
BCL6 overexpression in SHR reduced blood pressure, NLRP3 expression and inflammation in the renal cortex of SHR PMID:29072703
Although BCL6 controls follicular helper T cells activity in humans and mice, the role of miR-31 is restricted to human follicular helper T cell differentiation, reflecting a species specificity of the miR-31 action. PMID:29133396
Aberrant CD10 and BCL6 expression defines a subset of MCLs with higher mean Ki-67 index and higher prevalence of MUM1 expression PMID:28628241
BCL6 is a growth promoting factor in glioblastoma and glioma. PMID:28356518
IFN gamma induced upregulation of BCL6 was dependent on the classical STAT1 signaling pathway, and affected both major BCL6 variants. Interestingly, although IFN alpha induced stronger STAT1 phosphorylation than IFN gamma, it only slightly upregulated BCL6 in multiple myeloma lines. PMID:29510136
Findings demonstrate that BCL6 expression is downregulated by miR-519d which targets its 3 '-UTR. Also, BCL6 mediates the repression of miR-519d on cell proliferation and invasive capability of gastric cancer cells. PMID:29510377
In Pakistani population, the frequency of GCB type DLBCL [diffuse large B cell lymphoma ]expressing CD10 and BCL6 is 37.5%, and non- GCB type DLBCL [diffuse large B cell lymphoma ] expressing MUM1 is 62.5%. PMID:29056123
BCOR internal tandem duplication and/or nuclear immunoreactivity for BCOR or BCL6 can aid in the diagnosis of primitive myxoid mesenchymal tumor of infancy and help to differentiate it from congenital infantile fibrosarcoma. PMID:28256570
our findings provide a novel apoptotic regulatory pathway in which LITAF, as a transcription factor, inhibits the expression of BCL6, which leads to activation of the intrinsic mitochondrial pathway and tumor apoptosis. PMID:27764808
Ikaros regulates expression of the BCL6/BACH2 axis in acute lymphoblastic leukemia cells. PMID:28030830
our work casts new light on the biology of mantle cell lymphoma (MCL), revealing the role of SOX11 exerting a functional effect through the repression of BCL6 transcription in MCL cells PMID:26710884
BCL6 inhibitors have been shown to exert potent effects against these tumor types. Moreover, mechanism-based combinations of BCL6 inhibitors with other agents have yielded synergistic and often quite dramatic activity. Hence, there is a compelling case to accelerate the development of BCL6-targeted therapies for translation to the clinical setting PMID:27881582
High BCL6 expression is associated with good response to chemotherapy in acute lymphoblastic leukemia. PMID:27015556
BCL6 expression is present in isolated cortical neurons, granule cells in the cerebellum, scattered glial cells, and in some cells of the ependyma and choroid plexus. PMID:26862951
We show that human follicular lymphomas are dependent on BCL6 PMID:28232365
Aberrant BCL6 expression was strongly associated with poor reproductive outcomes in IVF cycles in women with unexplained infertility. PMID:29126613
EBNA3C inhibits the transcriptional activity of the Bcl6 promoter through interaction with the cellular protein IRF4. PMID:28738086
Data suggest that B-cell CLL/lymphoma 6 is a promising candidate as a single diagnostic biomarker for detection of endometriosis in women with otherwise unexplained infertility and may be associated with endometrial dysfunction, including progesterone resistance. PMID:27222232
The aim of this study was to investigate the clinical significance of three immune cell-related transcription factors, T-bet, GATA-3 and Bcl-6 in bladder cancer in Tunisian patients. PMID:27237631
analysis of role of BCL6 in maintaining activated B cell diffuse large B cell lymphoma reveals that ABC-DLBCL is a BCL6-dependent disease that can be targeted by rationally designed inhibitors that exceed the binding affinity of natural BCL6 ligands PMID:27482887
Results provide evidence that BCL6 overexpression is involved in genomic instability in multiple myeloma cells. PMID:28544233
Our data reveal a regulatory role of BCL6 in inhibiting antiviral resistance factors in follicular Th cells PMID:28550121
the high expressions of BCL6 and Lewis y antigen are associated with development, high tumor burden, and worse prognosis of ovarian cancer and targeting BCL6 could be a novel therapeutic strategy for ovarian cancer treatment. PMID:28671040
both mouse and human B cells, IFN-gamma synergized with B cell receptor, toll-like receptor, and/or CD40 activation signals to promote cell-intrinsic expression of the GC master transcription factor, B cell lymphoma 6 protein. PMID:27069113
MicroRNA-544 down-regulates both Bcl6 and Stat3 to inhibit tumor growth of human triple negative breast cancer PMID:27186677
miR-10a directly recognizes the 3'-UTR of the BCL6 transcript and regulated BCL6 expression. PMID:27815824
This work identified BCL6 as a novel biomarker for early prediction of cerebral palsy. PMID:28315684
Bcl-6 expression in circulating follicular helper-like T cells may represent a reliable marker for the disease activity in systemic lupus erythematosus PMID:27818202
In addition, subsequent single-crystal X-ray diffraction analysis of F1324/BCL6(5-129) complex revealed that the high affinity of F1324 was caused by effective interaction of its side chains while its main chain structure was similar to that of BcoR(Arg498-514Pro). To our knowledge, F1324 is the strongest BCL6-binding peptide yet reported. PMID:27856253
We report the case of a 7-month-old girl with atypical oculo-facio-cardio-dental syndrome (OFCD). A novel de novo pathogenic mutation in the BCL6 interacting co-repressor gene (BCOR) (c.4540C>T; p.Arg1514*), was identified on the X chromosome PMID:28317252
JAK2 is a direct BCL6 target gene; BCL6 bound to the JAK2 promoter PMID:27268052
Deregulated BCL6 expression caused by hypermethylation and TET2 mutations may result in skewed follicular helper T cell differentiation and eventually contribute to angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma development in patients PMID:27921272
miR-339-5p inhibits migration and invasion in ovarian cancer by targeting NACC1 and BCL6. miR-339-5p may be a biomarker of metastasis in ovarian cancer; NACC1 had a predictive value for ovarian cancer progression PMID:26553360
Data show there was a positive correlation between B cell lymphoma 6 (Bcl-6) and B lymphocyte-induced maturation protein 1 (Blimp-1) at the level of mRNA. PMID:27363279
miR-155 overexpression plays a promoting role in the proliferative, migratory and invasive behavior of OSCC cells. Its effects on OSCC are possibly associated with its regulation of the BCL6/cyclin D2 axis. PMID:26986233
BCL6 Rearrangements are associated with Diffuse Large B-Cell Lymphoma. PMID:26319027
Bcl6, by interacting with the co-factors NcoR2 and HDAC3, plays a pivotal role in controlling IRF7 induction and antiviral signaling priming. PMID:26728228
diffuse large B-cell lymphoma patients with either MYC/BCL6 rearrangements or MYC/BCL6 co-expression did not always have poorer prognosis PMID:26573234
BCL6 promotes proliferation and survival of trophoblastic cells. PMID:27029530
Studies indicate that germinal centers (GC) B cells represent the normal counterpart of most B-cell lymphomas, which are often characterized by deregulated B cell lymphoma 6 (BCL6) expression or BCL6-mediated pathways. PMID:26566802
Bcl-6 mRNA and protein levels, as well as the frequencies of Bcl-6(+)CD4(+) cells were significantly increased in polyp tissues compared with normal controls. PMID:25711734
Follicular helper T cells differentiation is a multistage process involving BCL6 and other transcription factors, cytokines, and costimulation through ICOS and several other molecules. (Review) PMID:26120879
These results suggest that STAT6 plays an important role in regulating Sp1 and BCL6 through STAT2 to exert the anti-proliferative effects of type I IFN. PMID:26945968
Identified BCL6 to be a target of miR-10a in patients with Acute Myeloid Leukemia (AML). PMID:26590574
Study demonstrates that survivin belongs to the Tfh cell phenotype and ensures their optimal function by regulating transcriptional activity of Bcl-6. PMID:26343374
BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy. PMID:21041953
Taken together, our results demonstrated that miR-187-3p played a pivotal role on NSCLC through inhibiting cell proliferation, migration, invasion, and promoting apoptosis by targeting oncogenic BCL6. PMID:26845350
BCL6 gene expression is plays a role in the pathogenesis of diffuse large B-cell lymphoma. PMID:26414904